First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.

[1]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[2]  A. Apolo,et al.  Targeted therapies in urothelial carcinoma , 2014, Current opinion in oncology.

[3]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[4]  Evan O. Paull,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[5]  J. Wolchok,et al.  Immune modulation in cancer with antibodies. , 2014, Annual review of medicine.

[6]  Shan Li,et al.  ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis , 2014, Anti-cancer drugs.

[7]  C. Sander,et al.  Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Chin,et al.  Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[9]  M. Dimopoulos,et al.  Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Pignon,et al.  ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. , 2013, The New England journal of medicine.

[11]  I. Ostrovnaya,et al.  Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Sylvester,et al.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Sylvester,et al.  Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Yasuo Ohashi,et al.  The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine‐cisplatin‐based combination chemotherapy , 2011, BJU international.

[15]  Cynthia S. Johnson,et al.  Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Bellmunt,et al.  Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches , 2011, Current oncology reports.

[17]  G. Sonpavde,et al.  A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. , 2011, The Lancet. Oncology.

[18]  Jeeyun Lee,et al.  Excision repair cross‐complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin‐based chemotherapy , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[19]  Y. Iwasaki,et al.  Phase II trial of weekly gemcitabine and split-dose cisplatin for advanced non-small-cell lung cancer. , 2009, Japanese journal of clinical oncology.

[20]  Jae K. Lee,et al.  Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. , 2009, Cancer research.

[21]  E. Messing,et al.  Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? , 2009, Urology.

[22]  N. Cook,et al.  Small cell carcinoma of the urinary bladder: a 15‐year retrospective review of treatment and survival in the Anglian Cancer Network , 2009, BJU international.

[23]  H. von der Maase,et al.  Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? , 2008, Acta oncologica.

[24]  Jae K. Lee,et al.  A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2007, Proceedings of the National Academy of Sciences.

[25]  J. Carles,et al.  Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  D. Amadori,et al.  Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. , 2007, European urology.

[27]  Y. Tsai,et al.  Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. , 2007, Urology.

[28]  P. Russo,et al.  Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. , 2007, Urology.

[29]  Yusuke Nakamura,et al.  Validation study of the prediction system for clinical response of M‐VAC neoadjuvant chemotherapy , 2007, Cancer science.

[30]  J. Baselga,et al.  Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Ahn,et al.  A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. , 2006, Lung cancer.

[32]  R. Crevoisier,et al.  A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  S. Ricci,et al.  Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .

[34]  Yusuke Nakamura,et al.  Predicting Response to Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Neoadjuvant Chemotherapy for Bladder Cancers through Genome-Wide Gene Expression Profiling , 2005, Clinical Cancer Research.

[35]  H. V. van Boven,et al.  Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. , 2005, Urology.

[36]  N. James,et al.  A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer , 2004, British Journal of Cancer.

[37]  J. Manola,et al.  Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium , 2004, Cancer.

[38]  R. Millikan,et al.  Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. , 2003, The Journal of urology.

[39]  J. Baselga,et al.  Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine , 2002, Cancer.

[40]  M. Alloisio,et al.  Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  J. Bellmunt,et al.  New chemotherapy combinations for advanced bladder cancer , 2001, Current opinion in urology.

[42]  L. Collette,et al.  Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  B. Redman,et al.  Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  W. Oh,et al.  Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  L. Crinò,et al.  Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  I. Tannock,et al.  Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Parmar,et al.  A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. , 1998, British Journal of Cancer.

[50]  A. Ribas,et al.  Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma , 1997, Cancer.

[51]  I. Tannock,et al.  Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  C. Logothetis,et al.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  N. Geller,et al.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.

[55]  D. Johnson,et al.  Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report. , 1977, JAMA.

[56]  A. Yagoda.  Future implications of phase 2 chemotherapy trials in ninety-five patients with measurable advanced bladder cancer. , 1977, Cancer research.

[57]  G. Pond,et al.  Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. , 2014, Urologic oncology.

[58]  Joon-Oh Park,et al.  Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract , 2009, Medical oncology.

[59]  L. Collette,et al.  Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.

[60]  J. Richie,et al.  Bladder cancer. Clinical practice guidelines in oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[61]  C. Logothetis,et al.  Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. , 1989, The Journal of urology.